中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.

文献类型:期刊论文

作者Wang, Rong; Wang, Xiaojia; Chen, Zhan-Hong; Niu, Jin; Huang, Yuan; Pan, Jiani; Ye, Weiwu; Cao, Wenming
刊名JOURNAL OF CLINICAL ONCOLOGY
出版日期2021-05-20
卷号39
ISSN号0732-183X
DOI10.1200/JCO.2021.39.15_suppl.e13069
资助项目National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province, China
WOS研究方向Oncology
语种英语
WOS记录号WOS:000708120300179
出版者LIPPINCOTT WILLIAMS & WILKINS
资助机构National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province, China
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/126644]  
专题中国科学院合肥物质科学研究院
作者单位1.Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China
2.Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
3.Zhejiang Canc Hosp, Hangzhou, Peoples R China
4.Burning Rock Biotech, Hangzhou, Peoples R China
5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China
6.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714
Wang, Rong,Wang, Xiaojia,Chen, Zhan-Hong,et al. Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA Wang, Rong.,Wang, Xiaojia.,Chen, Zhan-Hong.,Niu, Jin.,Huang, Yuan.,...&Cao, Wenming.(2021).Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA Wang, Rong,et al."Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).

入库方式: OAI收割

来源:合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。